Mall PA
BPC-157 NOT FOR HUMANS BANNED IN TESTED SPORT
File 02 · synthetic 15-amino-acid peptide fragment derived from a protein found in gastric juice

BPC-157

Also called: Body Protection Compound 157, pentadecapeptide BPC 157, PL 14736, bepecin

Banned · S0Very limited

BPC-157 is a lab-made 15-amino-acid peptide whose sequence comes from a larger protein isolated from human stomach juice. It has been studied mainly by one research group in Croatia, almost entirely in rats and cell cultures.

Why the gym talks about it

It is the best-known 'healing peptide' in gym culture, with a reputation for helping tendons, ligaments and the gut, and it is often paired with TB-500 in what people call the 'Wolverine stack'. That reputation rests far more on animal studies and anecdotes than on human trials.

What the research actually found

  • in vitro (rat cells)In cultured rat tendon fibroblasts, BPC-157 increased cell outgrowth, survival under stress and migration. Source
  • in vitro (rat cells)It increased growth hormone receptor expression in rat tendon fibroblasts. Source
  • animal (rat)A 2026 rat study of repaired Achilles tendons found higher load-to-failure with BPC-157 that did not reach statistical significance, while TB-500 alone showed significant gains in strength and tissue scores. Source
  • systematic review (mostly animal data)A 2025 systematic review found 36 studies on BPC-157 in muscle, tendon, ligament and bone injury: 35 were preclinical and 1 was a small human study. The authors called it promising but said human safety data are lacking. Source
  • small uncontrolled human reportsHuman data are limited to a retrospective phone survey of 16 knee-pain patients at one clinic with no control group, and a 2-person IV safety pilot that reported no changes in routine blood tests. Source

Human evidence: very limited. No randomized controlled trial in humans has been published; what exists is an uncontrolled chart-review survey and a 2-person safety pilot.

Tested lifters

S0 Non-Approved Substances. BPC-157 is named in S0 on the 2026 list, so it is prohibited at all times, in and out of competition.

High. A positive test is a violation. FDA's compounding changes do not affect WADA status. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.

FDA status

Not FDA-approved. FDA placed BPC-157 in Category 2 (significant safety risks) of the interim 503A bulks list in 2023. On April 15, 2026 FDA removed it and 11 other peptides from Category 2, but removal did not make them eligible for 503A compounding. FDA's Pharmacy Compounding Advisory Committee voted 8-6 (1 abstention) on July 23, 2026 to recommend BPC-157 for the 503A bulks list. That vote is non-binding, and as of Oct 1, 2026 no proposed rule or final decision has been found, so BPC-157 is not yet on the 503A bulks list. In late August 2026 FDA also issued warning letters to online peptide sellers, treating their products as unapproved new drugs.

As of 2026-10-01.

Known and theoretical risks

  • FDA cites possible immune reactions (immunogenicity) by some routes of administration and problems with peptide impurities and characterization of the active ingredient. Source
  • BPC-157 promotes blood-vessel growth (VEGFR2 activation) in animal and cell studies; some reviewers raise a theoretical concern about this in people with existing or undiagnosed cancers. It has not been tested. Source
  • There are no controlled human safety data, and gray-market products are unregulated, so contamination or mislabeling is possible. Source

Quick answers

Is BPC-157 banned for drug-tested lifters?

S0 Non-Approved Substances. BPC-157 is named in S0 on the 2026 list, so it is prohibited at all times, in and out of competition. High. A positive test is a violation. FDA's compounding changes do not affect WADA status. USA Powerlifting tests against the WADA list (https://www.usapowerlifting.com/tue/); other tested federations generally use WADA-style lists.

Is BPC-157 FDA approved?

Not FDA-approved. FDA placed BPC-157 in Category 2 (significant safety risks) of the interim 503A bulks list in 2023. On April 15, 2026 FDA removed it and 11 other peptides from Category 2, but removal did not make them eligible for 503A compounding. FDA's Pharmacy Compounding Advisory Committee voted 8-6 (1 abstention) on July 23, 2026 to recommend BPC-157 for the 503A bulks list. That vote is non-binding, and as of Oct 1, 2026 no proposed rule or final decision has been found, so BPC-157 is not yet on the 503A bulks list. In late August 2026 FDA also issued warning letters to online peptide sellers, treating their products as unapproved new drugs.

How strong is the human evidence for BPC-157?

Very limited. No randomized controlled trial in humans has been published; what exists is an uncontrolled chart-review survey and a 2-person safety pilot.

Sources

Research-use-only information file. Nothing here is medical advice or instructions for use. Not evaluated by the FDA. Talk to your doctor.

More files

Back to the basement